Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis.

BACKGROUND A recently proposed reclassification of lupus nephritis divides class IV (diffuse proliferative) lupus nephritis into those cases with predominantly segmental proliferative lesions (class IV-S) and those with predominantly global proliferative lesions (class IV-G). This report explores the validity of this distinction and possible differences in pathogenesis between the 2 types of lesions. METHODS Patients from a previously reported series of severe lupus nephritis, with initial biopsies (Bx1) and control biopsies (Bx2) at 6 months after induction therapy were reclassified according to the newly proposed classification. From the original series of 65 patients, 15 patients were reclassified as having class IV-S lesions and 31 patients class IV-G lesions. Clinical data at both biopsies and follow-up were available on all patients selected. RESULTS Patients with IV-G lesions had worse proteinuria, lower serum hemoglobins, lower CH50s, and likely higher SCrs (P = .06) and lower C3s (P = .08) than class IV-S patients. Serum CH50 and C3 correlated negatively with severity of class IV-G lesions, but not at all with class IV-S lesions. Patients with class IV-G lesions had greater overall immune deposits and subendothelial deposits on IF and greater hyaline deposits on light microscopy. By contrast, class IV-S showed predominant mesangial deposits and a much higher rate of glomerular fibrinoid necroses (13.3 +/- 15.3% vs. 5.6 +/- 8.0% of viable glomeruli, P = .03). Other distinctions included the fact that membranoproliferative features were found only in class IV-G lesions, and glomerular monocyte/macrophages were much more frequent in this group than in class IV-S lesions (1.77 +/- 0.92 vs. 0.86 +/- 0.77, P = .008). Finally, class IV-G frequently involved all viable glomeruli (74.2% of cases), whereas segmental proliferative lesions never did (P < .0001). Survivals from doubling of SCr at 10 years did not differ between the 2 types at Bx1: 72.5% segmental versus 60.4% global, P= .53. However, among those with persistent lesions at Bx 2 (11 IV-S and 9 IV-G), there was a dramatic difference in 10-year survivals between IV-S lesions (63.6%) and IV-G lesions (0%), P = .08. CONCLUSION There are definite clinical and morphologic differences between class IV-S and IV-G lesions. Data suggest that class IV-G lesions behave as an immune complex disease, having positive correlations with extent of immune deposits and negative correlations with serum complement levels, the model traditionally assumed for lupus nephritis as a whole. However, in class IV-S lesions, the presence of proportionally greater glomerular fibrinoid necroses and lack of correlation with extent of immune deposits suggest that these lesions may have a different pathogenesis.

[1]  N. Hisakawa,et al.  Anti-neutrophil cytoplasmic antibody in patients with systemic lupus erythematosus is unrelated to clinical features , 2005, Clinical Rheumatology.

[2]  Yasunori Iwata,et al.  The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. , 2004, Kidney international.

[3]  Shelley Hurwitz,et al.  New subcategories of class IV lupus nephritis: are there clinical, histologic, and outcome differences? , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  Lee Hebert,et al.  The classification of glomerulonephritis in systemic lupus erythematosus revisited. , 2004, Kidney international.

[5]  D. Isenberg,et al.  Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus , 2003, Lupus.

[6]  D. Yoo,et al.  Cytokine balance in kidney tissue from lupus nephritis patients. , 2003, Rheumatology.

[7]  P. Torguet,et al.  [Immunonegative necrotizing glomerulonephritis: an atypical case of lupus nephropathy]. , 2003, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[8]  P. Rieu,et al.  SLE and idiopathic nephrotic syndrome: coincidence or not? , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  Eric Thervet,et al.  Outcome of relapse in lupus nephritis: roles of reversal of renal fibrosis and response of inflammation to therapy. , 2002, Kidney international.

[10]  H. Hirakata,et al.  Genetically determined interferon-gamma production influences the histological phenotype of lupus nephritis. , 2002, Rheumatology.

[11]  V. D’Agati,et al.  Minimal change disease in systemic lupus erythematosus. , 2002, Clinical nephrology.

[12]  T. Ninomiya,et al.  Predominance of Th1 immune response in diffuse proliferative lupus nephritis. , 2001, Arthritis and rheumatism.

[13]  Joni K. Evans,et al.  Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. , 2001, Kidney international.

[14]  P. Rémy,et al.  Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. , 2001, Kidney international.

[15]  P. Rémy,et al.  A new morphologic index for the evaluation of renal biopsies in lupus nephritis. , 2000, Kidney international.

[16]  L. Truong,et al.  "Pauci-Immune" proliferative and necrotizing glomerulonephritis with thrombotic microangiopathy in patients with systemic lupus erythematosus and lupus-like syndrome. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  C. Ahn,et al.  Clinical Implications of Antineutrophil Cytoplasmic Antibody Test in Lupus Nephritis , 2000, American Journal of Nephrology.

[18]  M. Zhao,et al.  [The significance of antiendothelial cell antibodies in patients with lupus nephritis: a clinical and renal pathological study]. , 1999, Zhonghua yi xue za zhi.

[19]  A. Hida,et al.  Successful Treatment of Rapidly Progressive Lupus Nephritis Associated with Anti-MPO Antibodies by Intravenous Immunoglobulins , 1999, Clinical Rheumatology.

[20]  M. Zhao,et al.  Antineutrophil cytoplasmic autoantibodies (ANCA) and their target antigens in Chinese patients with lupus nephritis. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  H. Suzuki,et al.  [Renal microscopic polyarteritis replaced by pericarditis with episodic increases in MPO-ANCA in a patient with systemic lupus erythematosus]. , 1998, Nihon Jinzo Gakkai shi.

[22]  V. D’Agati,et al.  Membranous lupus nephritis with antineutrophil cytoplasmic antibody-associated segmental necrotizing and crescentic glomerulonephritis. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  D. Isenberg,et al.  Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Prevalence, specificities, and clinical significance. , 1995, Arthritis and rheumatism.

[24]  D. Gladman,et al.  Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. , 1994, The Journal of rheumatology.

[25]  R. Bernstein,et al.  Autoantibodies to myeloperoxidase in idiopathic and drug-induced systemic lupus erythematosus and vasculitis. , 1994, British journal of rheumatology.

[26]  D. Boumpas,et al.  Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. , 1994, Kidney international.

[27]  T. Chan,et al.  Antiendothelial cell antibodies in lupus: correlations with renal injury and circulating markers of endothelial damage. , 1993, The Quarterly journal of medicine.

[28]  C. Li,et al.  Antilactoferrin antibody in systemic lupus erythematosus. , 1992, British journal of rheumatology.

[29]  E. Ritz,et al.  Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. , 1992, Contributions to nephrology.

[30]  L R Muenz,et al.  Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. , 1984, Kidney international.

[31]  E. Lewis,et al.  Necrotizing glomerulitis of systemic lupus erythematosus. , 1983, Human pathology.